DK3710485T3 - Anti-sez6-antistof-lægemiddelkonjugater og anvendelsesfremgangsmåder - Google Patents

Anti-sez6-antistof-lægemiddelkonjugater og anvendelsesfremgangsmåder Download PDF

Info

Publication number
DK3710485T3
DK3710485T3 DK19732174.8T DK19732174T DK3710485T3 DK 3710485 T3 DK3710485 T3 DK 3710485T3 DK 19732174 T DK19732174 T DK 19732174T DK 3710485 T3 DK3710485 T3 DK 3710485T3
Authority
DK
Denmark
Prior art keywords
methods
sez6 antibody
conjugates
medicinal
medicinal conjugates
Prior art date
Application number
DK19732174.8T
Other languages
English (en)
Inventor
David Liu
Alexander Schammel
Julia Gavrilyuk
Original Assignee
Abbvie Stemcentrx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Stemcentrx Llc filed Critical Abbvie Stemcentrx Llc
Application granted granted Critical
Publication of DK3710485T3 publication Critical patent/DK3710485T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK19732174.8T 2018-05-30 2019-05-30 Anti-sez6-antistof-lægemiddelkonjugater og anvendelsesfremgangsmåder DK3710485T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862678061P 2018-05-30 2018-05-30
PCT/US2019/034701 WO2019232241A1 (en) 2018-05-30 2019-05-30 Anti-sez6 antibody drug conjugates and methods of use

Publications (1)

Publication Number Publication Date
DK3710485T3 true DK3710485T3 (da) 2021-05-10

Family

ID=66998493

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19732174.8T DK3710485T3 (da) 2018-05-30 2019-05-30 Anti-sez6-antistof-lægemiddelkonjugater og anvendelsesfremgangsmåder

Country Status (31)

Country Link
US (3) US20210196834A1 (da)
EP (2) EP3710485B8 (da)
JP (1) JP6936399B2 (da)
KR (1) KR20210018316A (da)
CN (1) CN112135843A (da)
AU (1) AU2019278870A1 (da)
BR (1) BR112020024223A2 (da)
CA (1) CA3097199A1 (da)
CL (1) CL2020003044A1 (da)
CO (1) CO2020016151A2 (da)
CR (1) CR20200623A (da)
CY (1) CY1124183T1 (da)
DK (1) DK3710485T3 (da)
EC (1) ECSP20082970A (da)
ES (1) ES2867148T3 (da)
HR (1) HRP20210631T1 (da)
HU (1) HUE053616T2 (da)
IL (1) IL278225A (da)
LT (1) LT3710485T (da)
MA (1) MA51453A (da)
MX (1) MX2020012788A (da)
NZ (1) NZ768778A (da)
PE (1) PE20211497A1 (da)
PH (1) PH12020551968A1 (da)
PL (1) PL3710485T3 (da)
PT (1) PT3710485T (da)
RS (1) RS61770B1 (da)
RU (1) RU2770474C1 (da)
SG (1) SG11202011576VA (da)
SI (1) SI3710485T1 (da)
WO (1) WO2019232241A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220152951A (ko) 2021-05-10 2022-11-17 강원대학교산학협력단 항체 결합 재조합 융합 단백질 및 이를 이용한 항체-약물 접합체
US20240091374A1 (en) * 2022-08-26 2024-03-21 Abbvie Inc. Anti-sez6 antibody drug conjugates

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2532858B2 (ja) 1985-04-01 1996-09-11 セルテツク リミテツド 形質転換したミエロ―マ細胞系
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5879936A (en) 1988-04-18 1999-03-09 Aluguisse Holding A.G. Recombinant DNA methods, vectors and host cells
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
EP1507556B1 (en) * 2002-05-02 2016-07-27 Wyeth Holdings LLC Calicheamicin derivative-carrier conjugates
AR048098A1 (es) * 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
EP2336177A1 (en) 2004-08-04 2011-06-22 Amgen, Inc Antibodies to DKK-1
CN106620693A (zh) 2010-09-03 2017-05-10 艾伯维施特姆森特克斯有限责任公司 新型调节剂及使用方法
SG10201801444WA (en) * 2012-02-24 2018-04-27 Abbvie Stemcentrx Llc Anti sez6 antibodies and methods of use
WO2015003154A1 (en) 2013-07-03 2015-01-08 Histosonics, Inc. Articulating arm limiter for cavitational ultrasound therapy system
CN105848671B (zh) * 2013-08-28 2019-12-13 艾伯维施特姆森特克斯有限责任公司 位点特异性抗体缀合方法和组合物
KR20160046914A (ko) * 2013-08-28 2016-04-29 스템센트알엑스 인코포레이티드 신규한 ｓｅｚ6 조절물질 및 사용방법
MA41645A (fr) * 2015-03-04 2018-01-09 Abbvie Stemcentrx Llc Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation
TW201713363A (zh) * 2015-04-21 2017-04-16 史坦森特瑞斯公司 卡奇黴素構建體及使用方法
CA3009484A1 (en) * 2015-12-22 2017-06-29 Abbvie Stemcentrx Llc Novel anti-mmp16 antibodies and methods of use
CN109563167A (zh) * 2016-06-08 2019-04-02 艾伯维公司 抗b7-h3抗体和抗体药物偶联物

Also Published As

Publication number Publication date
US20210196834A1 (en) 2021-07-01
HUE053616T2 (hu) 2021-07-28
EP3858863A1 (en) 2021-08-04
SI3710485T1 (sl) 2021-08-31
US20210338831A1 (en) 2021-11-04
EP3710485B8 (en) 2021-06-23
CL2020003044A1 (es) 2021-04-16
WO2019232241A1 (en) 2019-12-05
PE20211497A1 (es) 2021-08-11
EP3710485A1 (en) 2020-09-23
HRP20210631T1 (hr) 2021-05-28
JP2021508694A (ja) 2021-03-11
RS61770B1 (sr) 2021-05-31
ECSP20082970A (es) 2021-01-29
IL278225A (en) 2020-11-30
CY1124183T1 (el) 2022-05-27
PH12020551968A1 (en) 2021-09-13
LT3710485T (lt) 2021-05-10
US20200316215A1 (en) 2020-10-08
CN112135843A (zh) 2020-12-25
CO2020016151A2 (es) 2021-05-31
JP6936399B2 (ja) 2021-09-15
CA3097199A1 (en) 2019-12-05
BR112020024223A2 (pt) 2021-03-16
US11077203B2 (en) 2021-08-03
KR20210018316A (ko) 2021-02-17
MA51453A (fr) 2020-09-23
AU2019278870A1 (en) 2020-10-29
CR20200623A (es) 2021-07-01
PL3710485T3 (pl) 2021-09-13
PT3710485T (pt) 2021-05-04
SG11202011576VA (en) 2020-12-30
RU2770474C1 (ru) 2022-04-18
MX2020012788A (es) 2021-02-15
NZ768778A (en) 2022-07-01
ES2867148T3 (es) 2021-10-20
EP3710485B1 (en) 2021-03-31

Similar Documents

Publication Publication Date Title
DK3383916T3 (da) Anti-CD73-antistoffer og anvendelser deraf
DK3618863T3 (da) Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
DK3458479T3 (da) Anti-b7-h3-antistoffer og antistof-lægemiddelkonjugater
DK3601358T3 (da) Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
DK3610005T3 (da) Peptidligase og anvendelse deraf
DK3653221T3 (da) Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
DK3946464T3 (da) Forbindelser og konjugater deraf
DK3411398T3 (da) Målrettede terapeutiske midler og anvendelse heraf
DK3443009T3 (da) Anti-tim-3-antistoffer og sammensætninger
DK3707159T3 (da) Hidtil ukendte modificerede t-cellereceptorer og immunterapi med anvendelse deraf
DK3504242T3 (da) Anti-ox40-antistoffer og anvendelse deraf
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3557998T3 (da) Sammensætninger, kompositioner og anvendelsesmetoder
DK3595653T3 (da) Sammensætninger af plinabulin og anvendelse heraf
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3529257T3 (da) Oxysteroler og fremgangsmåder til anvendelse deraf
DK3618928T3 (da) Anti-Sortilin-antistoffer og fremgangsmåder til anvendelse deraf
DK3658192T3 (da) Glucocorticoid-receptoragonist og immunokonjugater deraf
DK3536698T3 (da) Lanosterol-prodrugforbindelse og anvendelse deraf
DK3532459T3 (da) Lsd1-hæmmere og medicinske anvendelser deraf
DK3430129T3 (da) Kolonidannende medium og anvendelse deraf
DK3621694T3 (da) Lrrc33-inhibitorer og anvendelse heraf
DK3253800T3 (da) Prostata antigen standarder og bruge deraf
DK3692009T3 (da) Biocementationsfremgangsmåde og system